Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications

Clinical Chemistry

Volumn 46, Issue 1, 2000, Pages 47-54

  Jung, Klaus ^a   Brux, Brigitte ^a   Lein, Michael ^a   Rudolph, Birgit ^a   Kristiansen, Glen ^a   Hauptmann, Steffen ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Sinha, Pranav ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GEL FILTRATION; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOBLOTTING; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY;

EID: 0033952926     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.1.47     Document Type: Article

References (34)

1. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
2. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
3. 3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
4. 4. Meyer A, Jung K, Lein M, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate specific antigen in serum. Int J Cancer 1997;74:630-6.
5. 5. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
6. 6. Stenman U-H. Prostate-specific antigen, clinical use and staging: an overview. Br J Urol 1997;79(Suppl 1):53-60.
7. 1-Antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43:427-34.
8. 8. Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157:2166-70.
9. 9. Huber PR, Schmid HP, Mattarelli G, Strittmatter B, Vansteenbrugge GJ, Maurer A. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995;27:212-9.
10. 10. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-23.
11. 1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared to total PSA and percentage free PSA. Urology 1999;53:1160-8.
12. 12. Laemmli UK. Cleavage of structural proteins during assembling of the head of bacteriophage T4. Nature 1970;227:680-5.
13. 13. Dunn MJ. Determination of total protein concentration. In: Harris ELV, Angal S, eds. Protein purification methods. Oxford: IRL Press, 1992:10-8.
14. 14. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-52.
15. 15. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
16. 16. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
17. 17. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41:1567-73.
18. 18. Chu LF, Chen Z, Stamey TA. Different molecular forms of uncomplexed prostate specific antigen (PSA) show similar immunoreactivities. J Urol 1999;161:2009-12.
19. 19. Charrier J-P, Tournel C, Michel S, Dalbon P, Jolivet M. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis 1999;20:1075-81.
20. 2-macroglobulin and complement C4 in human benign prostatic hyperplasia. Urol Res 1983;11:275-7.
21. 1-protease inhibitor in serum. Clin Chem 1999;45:814-21.
22. 1-antichymotrypsin in human prostate cancer. Br J Urol 1996;77:107-12.
23. 23. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
24. 24. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 1991;49:645-9.
25. 25. Culkin DJ, Gelder FB, Mata JA, Zitman RI, Venable DD. Cellular PSA in benign and malignant prostate. Prostate 1995;26:1-4.
26. 26. Blijenberg BG, Storm BN, Kruger Boeken AE, Schröder FH. On the standardisation of total prostate-specific antigen: an exercise with two reference preparations. Clin Chem Lab Med 1999;37:545-52.
27. 27. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
28. 28. Abrahamsson P-A, Lilja H, Falkmer S, Wadström LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.
29. 29. Henttu P, Lukkarinen O, Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990;45: 654-60.
30. 30. Gallee MP, Visser dJ, van der Korput JA, van der Kwast TH, ten Kate FJ, Schroeder FH, Trapman J. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res 1990;18:181-7.
31. 31. Hakalahti L, Vihko P, Henttu P, Autio HH, Soini Y, Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 1993;55:590-7.
32. 32. Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fossa SD. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/MO prostatic adenocarcinoma. Br J Urol 1995;75:26-32.
33. 33. Stege RH, Tribukait B, Carlstrom KA, Grande M, Pousette AH. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 1999;38:183-8.
34. 34. Pousette A, Carlström K, Tribukait B, Grande M, Engström A-H, Henriksson P, Stege R. Prostate-specific antigen in tissue from fine-needle aspiration biopsies. Br J Urol 1997;79(Suppl 1): 104-6.